ARTICLE | Company News
Certriad NDA gets complete response
March 31, 2010 1:30 AM UTC
FDA issued a complete response letter for an NDA for Certriad rosuvastatin/fenofibric acid from Abbott Laboratories (NYSE:ABT) and AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat mixed dyslipidemia. The ...